Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728937 | 0.84 | POLB (0.50) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL22798569 | 0.81 | POLB (0.44) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL8196306 | 0.81 | POLB (0.44) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL670165 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL670164 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL5567091 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL15500843 | 0.79 | L3MBTL1 (0.48) | POLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6305195 | 0.76 | POLB (0.52) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL6764378 | 0.75 | SYK (0.41) | POLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL234454 | 0.74 | LMNA (0.62) | POLBSMN1; SMN2LMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20170319517-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | THE GENERAL HOSPITAL CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-9603817-B2 | Methods, compositions, and kits for treating pain and pruritis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150087714-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-03-26 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8492354-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8481502-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120184501-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 637/4885SMN1; SMN2 2865/4885LMNA 2137/4885 |
| US-20170319517-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | POLB 3860/4885SMN1; SMN2 4817/4885LMNA 2184/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 767/4885SMN1; SMN2 2873/4885LMNA 2144/4885 |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, MRPS23 | POLB 994/4885SMN1; SMN2 3040/4885LMNA 2240/4885 |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 827/4885SMN1; SMN2 2836/4885LMNA 2061/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 794/4885SMN1; SMN2 2893/4885LMNA 2099/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | POLB 4448/4885SMN1; SMN2 1712/4885LMNA 2620/4885 |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | POLB 3860/4885SMN1; SMN2 4817/4885LMNA 2184/4885 |
| US-20150087714-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPA1 | POLB 3851/4885SMN1; SMN2 4808/4885LMNA 2197/4885 |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 827/4885SMN1; SMN2 2836/4885LMNA 2061/4885 |
| US-20120184501-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | POLB 687/4885SMN1; SMN2 1821/4885LMNA 2015/4885 |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | POLB 592/4885SMN1; SMN2 2435/4885LMNA 2249/4885 |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ATP6V1B1, GLS, NRDC | POLB 1858/4885SMN1; SMN2 4505/4885LMNA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.